Evidence map›Paper›PMID 36869917›Full record

ArticleAnnals of surgical oncology2023

Association Between Metastatic Pattern and Prognosis in Stage IV Gastric Cancer: Potential for Stage Classification Reform.

Peter L Zhan, Maureen E Canavan, Theresa Ermer, Matthew D Pichert, Andrew X Li, Richard C Maduka, Brooks V Udelsman, Attila Nemeth, Daniel J Boffa

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Peter L ZhanDivision of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT, USA.
Maureen E CanavanCancer Outcomes Public Policy and Effectiveness Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
Theresa ErmerDivision of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT, USA.
Matthew D PichertDivision of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT, USA.
Andrew X LiDivision of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT, USA.
Richard C MadukaDivision of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT, USA.
Brooks V UdelsmanDivision of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT, USA.
Attila NemethDepartment of Thoracic and Cardiovascular Surgery, University Hospital Tübingen, 72076, Tübingen, Germany.
Daniel J BoffaDivision of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT, USA. Daniel.boffa@yale.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aims to clarify the association between metastatic pattern and prognosis in stage IV gastric cancer, with a focus on patients presenting with metastases limited to nonregional lymph nodes.

methodsIn this retrospective cohort study, the National Cancer Database was used to identify patients ≥ 18 years of age diagnosed with stage IV gastric cancer between 2016 and 2019. Patients were stratified according to pattern of metastatic disease at diagnosis: nonregional lymph nodes only ("stage IV-nodal"), single systemic organ ("stage IV-single organ"), or multiple organs ("stage IV-multi-organ"). Survival was assessed by Kaplan-Meier curves and multivariable Cox models in unadjusted and propensity score-matched samples.

resultsOverall, 15,050 patients were identified, including 1,349 (8.7%) stage IV-nodal patients. Most patients in each group received chemotherapy [68.6% of stage IV-nodal patients, 65.2% of stage IV-single organ patients, and 63.5% of stage IV-multi-organ patients (p = 0.003)]. Stage IV-nodal patients exhibited better median survival (10.5 months, 95% CI 9.7-11.9, p < 0.001) than single organ (8.0, 95% CI 7.6-8.2) and multi-organ (5.7, 95% CI 5.4-6.0) patients. In the multivariable Cox model, stage IV-nodal patients also exhibited better survival (HR 0.79, 95% CI 0.73-0.85, p < 0.001) than single organ (reference) and multi-organ (HR 1.27, 95% CI 1.22-1.33, p < 0.001) patients.

conclusionsNearly 9% of clinical stage IV gastric cancer patients have their distant disease confined to nonregional lymph nodes. These patients were managed similarly to other stage IV patients but experienced a better prognosis, suggesting opportunities to introduce M1 staging subclassifications.

Indexed as

Stomach NeoplasmsHumansLymphatic MetastasisNeoplasm StagingPrognosisProportional Hazards ModelsRetrospective Studies

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.